{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:49:52Z","timestamp":1787759392062,"version":"build-2784847793"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cmi.2024.12.036","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:14:29Z","timestamp":1735614869000},"page":"740-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["What is the most effective antibiotic monotherapy for severe Pseudomonas aeruginosa infection? A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"31","author":[{"given":"Dorit","family":"Tekes-Manuva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Babich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Kozlovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erez","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.12.036_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajic.2004.10.001","article-title":"National nosocomial infections surveillance (NNIS) system report, data summary from january 1992 through june 2004, issued october 2004","volume":"32","year":"2004","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2024.12.036_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/596709","article-title":"Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?","volume":"48","author":"Schechner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2169\/internalmedicine.51.5698","article-title":"Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa","volume":"51","author":"Horino","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib4","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/cid\/ciz668","article-title":"Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection: a multisite retrospective study","volume":"70","author":"Babich","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.12.036_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2013.09.002","article-title":"Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies","volume":"42","author":"Hu","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.12.036_bib7","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1128\/AAC.01230-13","article-title":"Systematic review and meta-analysis of in\u00a0vitro synergy of polymyxins and carbapenems","volume":"57","author":"Zusman","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jgar.2019.09.016","article-title":"In\u00a0vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: a two-centre study","volume":"20","author":"Mirza","year":"2020","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2024.12.036_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2466-10-45","article-title":"Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review","volume":"10","author":"Zilberberg","year":"2010","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib10","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2024.12.036_bib11","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2024.12.036_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0002-9343(88)90140-4","article-title":"Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients","volume":"84","author":"Anaissie","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A\u00a0phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib14","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archsurg.1997.01430360040008","article-title":"A\u00a0randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group","volume":"132","author":"Barie","year":"1997","journal-title":"Arch Surg"},{"key":"10.1016\/j.cmi.2024.12.036_bib15","first-page":"243","article-title":"Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem\/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia","volume":"25","author":"Bartoloni","year":"1999","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.cmi.2024.12.036_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/42.4.511","article-title":"Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer)","volume":"42","author":"Biron","year":"1998","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C","article-title":"Beta-lactam regimens for the febrile neutropenic patient","volume":"65","author":"Bodey","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2024.12.036_bib18","first-page":"324","article-title":"Piperacillin\/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study","volume":"3","author":"B\u00f6hme","year":"1998","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.cmi.2024.12.036_bib19","series-title":"Febrile neutropenia","first-page":"63","article-title":"Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients","author":"Breen","year":"1997"},{"key":"10.1016\/j.cmi.2024.12.036_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1128\/AAC.33.1.87","article-title":"Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients","volume":"33","author":"Chan","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/00365540410017590","article-title":"A\u00a0prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies","volume":"36","author":"Cherif","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00000658-200008000-00016","article-title":"Comparison of intravenous\/oral ciprofloxacin plus metronidazole versus piperacillin\/tazobactam in the treatment of complicated intraabdominal infections","volume":"232","author":"Cohn","year":"2000","journal-title":"Ann Surg"},{"key":"10.1016\/j.cmi.2024.12.036_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/38.3.523","article-title":"Intravenous meropenem versus imipenem\/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group","volume":"38","author":"Colardyn","year":"1996","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0002-9343(85)90137-8","article-title":"Comparative study of ticarcillin plus clavulanate potassium versus piperacillin in the treatment of hospitalized patients with urinary tract infections","volume":"79","author":"Cox","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinids\/21.1.86","article-title":"A\u00a0multicenter comparative study of meropenem and imipenem\/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients","volume":"21","author":"Cox","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1015-9584(09)60039-7","article-title":"Randomized comparison of piperacillin\/tazobactam versus imipenem\/cilastatin in the treatment of patients with intra-abdominal infection","volume":"27","author":"Erasmo","year":"2004","journal-title":"Asian J Surg"},{"key":"10.1016\/j.cmi.2024.12.036_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/sur.2005.6.269","article-title":"Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study","volume":"6","author":"Fabian","year":"2005","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.cmi.2024.12.036_bib30","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1200\/JCO.2000.18.21.3690","article-title":"Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial","volume":"18","author":"Feld","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2024.12.036_bib31","first-page":"35","article-title":"Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime","volume":"10","author":"Finch","year":"1998","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1128\/AAC.38.3.547","article-title":"Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group","volume":"38","author":"Fink","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib33","doi-asserted-by":"crossref","first-page":"176S","DOI":"10.1016\/0002-9343(89)90052-1","article-title":"Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections","volume":"87","author":"Gallis","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/BF01700407","article-title":"Prospective, randomised, multicentre study of meropenem versus imipenem\/cilastatin as empiric monotherapy in severe nosocomial infections","volume":"16","author":"Garau","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib35","doi-asserted-by":"crossref","first-page":"169S","DOI":"10.1016\/0002-9343(89)90051-X","article-title":"Intravenous\/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections","volume":"87","author":"Gaut","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib36","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1016\/0002-9343(89)90042-9","article-title":"Intravenous\/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure","volume":"87","author":"Gentry","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib37","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.35.11.2371","article-title":"Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects","volume":"35","author":"Gentry","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.1016\/j.cmi.2024.12.036_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/36.suppl_A.191","article-title":"Meropenem versus imipenem\/cilastatin in intra-abdominal infections requiring surgery","volume":"36","author":"Geroulanos","year":"1995","journal-title":"Meropenem Study Group J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/341026","article-title":"Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial","volume":"35","author":"Graham","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib40","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/jac\/dkr344","article-title":"A\u00a0randomized trial of the efficacy and safety of sequential intravenous\/oral moxifloxacin monotherapy versus intravenous piperacillin\/tazobactam followed by oral amoxicillin\/clavulanate for complicated skin and skin structure infections","volume":"66","author":"Gyssens","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib41","doi-asserted-by":"crossref","first-page":"113S","DOI":"10.1016\/0002-9343(89)90036-3","article-title":"Ciprofloxacin (intravenous\/oral) versus ceftazidime in lower respiratory tract infections","volume":"87","author":"Haddow","year":"1989","journal-title":"Am J Med"},{"issue":"Suppl A","key":"10.1016\/j.cmi.2024.12.036_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0195-6701(90)90081-X","article-title":"Comparative clinical trial of ceftazidime and imipenem\/cilastatin in patients with severe nosocomial pneumonias and septicaemias","volume":"15","author":"Hartenauer","year":"1990","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.cmi.2024.12.036_bib43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000196675","article-title":"Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem\/cilastatin and ceftazidime","volume":"64","author":"Ho","year":"1997","journal-title":"Respiration"},{"issue":"Suppl B","key":"10.1016\/j.cmi.2024.12.036_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/32.suppl_B.175","article-title":"International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections","volume":"32","author":"Hoepelman","year":"1993","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib45","first-page":"1039","article-title":"A\u00a0randomized controlled clinical trial on piperacillin\/tazobactam versus ticarcillin\/clavulanic acid for the treatment of bacterial infections","volume":"111","author":"Hou","year":"1998","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cmi.2024.12.036_bib46","first-page":"1849","article-title":"A\u00a0randomized, controlled clinical trial on meropenem versus imipenem\/cilastatin for the treatment of bacterial infections","volume":"115","author":"Hou","year":"2002","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cmi.2024.12.036_bib47","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/AAC.42.11.2966","article-title":"Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis","volume":"42","author":"Jaccard","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ctr.12685","article-title":"Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia","volume":"30","author":"Jing","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2024.12.036_bib49","doi-asserted-by":"crossref","first-page":"274S","DOI":"10.1016\/0002-9343(89)90079-X","article-title":"Intravenous ciprofloxacin as empirical treatment of febrile neutropenic patients","volume":"87","author":"Kelsey","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib50","doi-asserted-by":"crossref","first-page":"R218","DOI":"10.1186\/cc11862","article-title":"A\u00a0randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia","volume":"16","author":"Kollef","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2024.12.036_bib51","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib52","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1016\/0002-9343(89)90049-1","article-title":"Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections","volume":"87","author":"Levine","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib53","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.34.7.1336","article-title":"Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients","volume":"34","author":"Liang","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib54","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2024.12.036_bib55","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib56","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/01.sla.0000230024.84190.a8","article-title":"Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections","volume":"244","author":"Malangoni","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.cmi.2024.12.036_bib58","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib59","first-page":"376","article-title":"A\u00a0comparative study on aztreonam, ceftazidime and amikacin in the treatment of complicated urinary tract infections","volume":"3","author":"Melekos","year":"1991","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0924-8579(01)00481-2","article-title":"Piperacillin 2 g\/tazobactam 0.5 g is as effective as imipenem 0.5 g\/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections","volume":"19","author":"Naber","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.12.036_bib61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00007611-199504000-00003","article-title":"Meropenem versus imipenem\/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections","volume":"88","author":"Nichols","year":"1995","journal-title":"South Med J"},{"key":"10.1016\/j.cmi.2024.12.036_bib62","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A\u00a0randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib63","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/jac\/31.6.927","article-title":"Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem\/cilastatin. European Study Group","volume":"31","author":"Norrby","year":"1993","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib64","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0732-8893(99)00085-1","article-title":"Cefepime versus ceftazidime for the treatment of serious bacterial infections","volume":"35","author":"Ponce-de-Le\u00f3n","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib66","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib67","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A\u00a0randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.12.036_bib68","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1016\/0002-9343(89)90058-2","article-title":"Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime","volume":"87","author":"Quintero-Perez","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib69","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1386::AID-CNCR25>3.0.CO;2-X","article-title":"A\u00a0comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients","volume":"77","author":"Raad","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2024.12.036_bib70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archinte.1992.00400140037010","article-title":"A\u00a0comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients","volume":"152","author":"Rolston","year":"1992","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2024.12.036_bib71","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2165\/00003495-199500492-00127","article-title":"Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients","volume":"49","author":"Siami","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2024.12.036_bib72","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A\u00a0phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib74","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.37.8.1580","article-title":"Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin\/Tazobactam Skin and Skin Structure Study Group","volume":"37","author":"Tan","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib75","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00535-009-0067-1","article-title":"Clinical efficacy of intravenous ciprofloxacin in patients with biliary tract infection: a randomized controlled trial with carbapenem as comparator","volume":"44","author":"Tazuma","year":"2009","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cmi.2024.12.036_bib76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/36.1.185","article-title":"Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients","volume":"36","year":"1995","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib77","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A\u00a0randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib78","first-page":"317","article-title":"[Meropenem (Merrem) vs imipenem\/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study]","volume":"52","author":"Tonelli","year":"1997","journal-title":"Minerva Chir"},{"key":"10.1016\/j.cmi.2024.12.036_bib79","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/thorax.55.12.1033","article-title":"Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem\/cilastatin","volume":"55","author":"Torres","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2024.12.036_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib81","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1016\/0002-9343(89)90037-5","article-title":"Randomized study of intravenous\/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections","volume":"87","author":"Trenholme","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib82","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1469-0691.2000.00082.x","article-title":"Meropenem versus imipenem\/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit","volume":"6","author":"Verwaest","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.12.036_bib83","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib84","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10156-013-0552-6","article-title":"Prospective randomized comparison study of piperacillin\/tazobactam and meropenem for healthcare-associated pneumonia in Japan","volume":"19","author":"Yamamoto","year":"2013","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0924-8579(98)00104-6","article-title":"Meropenem (1.5 g\/day) is as effective as imipenem\/cilastatin (2 g\/day) for the treatment of moderately severe intra-abdominal infections","volume":"11","author":"Zanetti","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.12.036_bib87","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib88","doi-asserted-by":"crossref","first-page":"526","DOI":"10.47102\/annals-acadmedsg.V43N11p526","article-title":"Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia","volume":"43","author":"Tan","year":"2014","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.cmi.2024.12.036_bib89","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0732-8893(01)00287-5","article-title":"Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from\u00a0urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib90","first-page":"1386","article-title":"Prevalence and fluoroquinolone resistance of Pseudomonas aeruginosa in a hospital of South China","volume":"8","author":"Yang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.cmi.2024.12.036_bib91","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijantimicag.2018.04.011","article-title":"Carbapenems vs. alternative \u03b2-lactams for the treatment of nosocomial pneumonia: a systematic review and meta-analysis","volume":"52","author":"O\u2019Donnell","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.12.036_bib92","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1128\/AAC.00381-08","article-title":"In\u00a0vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States","volume":"52","author":"Pillar","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/AAC.34.1.52","article-title":"Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa","volume":"34","author":"Trias","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib94","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1128\/AAC.34.5.685","article-title":"Diffusion of beta-lactam antibiotics through liposome membranes reconstituted from purified porins of the outer membrane of Pseudomonas aeruginosa","volume":"34","author":"Satake","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.036_bib95","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/0091270009355160","article-title":"Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections","volume":"50","author":"Zhang","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2024.12.036_bib96","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gendis.2019.04.001","article-title":"Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review","volume":"6","author":"Pachori","year":"2019","journal-title":"Genes Dis"},{"key":"10.1016\/j.cmi.2024.12.036_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02671-16","article-title":"Increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa as compared to other bacteria. Results of a 13-year prospective cohort study","volume":"61","author":"Thaden","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24006438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24006438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:14:01Z","timestamp":1777641241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24006438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1198743X24006438"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.12.036","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the most effective antibiotic monotherapy for severe Pseudomonas aeruginosa infection? A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}